Future stent drug delivery systems

Minerva Cardioangiologica

Volumn 56, Issue 1, 2008, Pages 155-166

  Caixeta, A ^a   Abizaid, A ^b,c   Aoki, J ^d   Dangas, G ^b,c   Mehran, R ^b,c,d  

^a Heart Institute   (Brazil)

^b Department of Medicine   (United States)

^c CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^d NONE

Author keywords

Coronary artery disease; Coronary restenosis; Drug eluting stents; Thrombosis

Indexed keywords

EVEROLIMUS; PACLITAXEL; PIMECROLIMUS; RAPAMYCIN; TACROLIMUS; ZOTAROLIMUS;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; HUMAN; IN-STENT RESTENOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOSIS;

ABSORBABLE IMPLANTS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POLYMERS; PROSTHESIS DESIGN; SIROLIMUS; TACROLIMUS;

EID: 42049095256     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Grüntzig AR. Transluminal dilatation of coronary-artery stenosis [letter]. Lancet 1978;1:263.
2. Grüntzig AR, Senning A, Siegenthaler WE. Non-operative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G et al. Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
4. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I et al. Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
5. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. Ann Intern Med 2003;138:777-86.
6. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346:1773-80.
7. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
8. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-7.
9. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. A polymer- based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
10. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease. JAMA 2005;294:1215-23.
11. Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007;28:2578-82.
12. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M et al. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;28:2706-13.
13. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, Cohen BM et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus- Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol 2006;47:1350-5.
14. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-21.
15. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
16. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
17. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents. Am J Med 2006;119:1056-61.
18. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol 2006;48:2584-91.
19. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice. Lancet 2007;369:667-8.
20. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
21. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-97.
22. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-9.
23. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
24. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356:1020-9.
25. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109:701-5.
26. Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-81.
27. Hofma SH, van der Giessen WJ, van Dalen BM, Lemos PA, McFadden EP, Sianos G et al. Indication of long-term endothelial dysfunction after sirolimus- eluting stent implantation. Eur Heart J 2006;27:166-70.
28. Babinska A, Markell MS, Salifu MO, Akoad M, Ehrlich YH, Kornecki E. Enhancement of human platelet aggregation and secretion induced by rapamycin. Nephrol Dial Transplant 1998;13:3153-9.
29. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8.
30. Schwartz RS, Chronos NA, Virmani R. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. J Am Coll Cardiol 2004;44:1373-85.
31. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
32. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003;108:1701-6.
33. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
34. Takano M, Ohba T, Inami S, Seimiya K, Sakai S, Mizuno K. Angioscopic differences in neointimal coverage and in persistence of thrombus between sirolimus-eluting stents and bare metal stents after a 6-month implantation. Eur Heart J 2006;27:2189-95.
35. Guagliumi G, Farb A, Musumeci G, Valsecchi O, Tespili M, Motta T et al. Images in cardiovascular medicine. Sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 2003;107:1340-1.
36. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41.
37. Siqueira DA, Abizaid AA, Costa JD, Feres F, Mattos LA, Staico R et al. Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes. Eur Heart J 2007;11:1304-9.
38. Ako J, Bonneau HN, Honda Y, Fitzgerald PJ. Design criteria for the ideal drug-eluting stent. Am J Cardiol 2007;100:3M-9M.
39. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21.
40. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, Hausleiter J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41:1283-8.
41. Abizaid A, Costa JJ, Whitbourn R, Chang J. The CardioMind coronary stent delivery system: stent delivery on a .014″ guidewire platform. Eurointervention 2007;3:154-7.
42. Louvard Y, Thomas M, Dzavik V, Hildick-Smith D, Galassi AR, Pan M et al. Classification of coronary artery bifurcation lesions and treatments: Time for a consensus! Catheter Cardiovasc Interv 2007 [Epub ahead of print].
43. Sukhija R, Mehta JL, Sachdeva R. Present status of coronary bifurcation stenting. Clin Cardiol 2007 [Epub ahead of print].
44. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG et al. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol 2005;46:1002-5.
45. Daemen J, Serruys PW. Drug-Eluting Stent Update 2007. Part I: A survey of current and future generation drug-eluting stents: Meaningful Advances or more of the same? Circulation 2007;116:316-28.
46. Grube E. The next generation of drug-eluting stents: are there meaningful differences? Presented at Transcatheter Cardiovascular Therapeutics Washington. DC October 2007
47. Nakamura M, Abizaid A, Hirohata A, Honda Y, Sousa JE, Fitzgerald PJ, Efficacy of reduced-dose sirolimus-eluting stents in the human coronary artery: Serial IVUS analysis of neointimal hyperplasia and luminal dimension. Catheter Cardiovasc Interv 2007;70:946-51.
48. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
49. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-8.
50. Tsujino I, Ako J, Honda Y, Fitzgerald PJ. Drug delivery via nano-micro and macroporous coronary stent surfaces. Expert Opin Drug Deliv 2007;4:287-95.
51. Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First in Man) Registry. J Am Coll Cardiol 2005;45:1574-9.
52. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF et al. Sustained suppression of neointimal proliferation by sirolimus- eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-11.
53. Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J 2001;22:2125-30.
54. Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 2005;46:1670-6.
55. Schofer J, Schluter M, Gershlick AH, Wijns W, Garcia E, Schampaert E et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9.
56. Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-5.
57. Lemos PA, Serruys PW, van Domburg RT, Saia F, Arampatzis CA, Hoye A et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109:190-5.
58. Ramcharitar S, Vaina S, Serruys PW. The next generation of drug-eluting stents: what's the horizon? Am J Cardiovasc Drugs 2007;7:81-93.
59. Hai-bo L, Bo X, QIAO Shu-bin, YANG Yue-jin, MA Wei-hua, QIN Xue-wen et al. A comparison of clinical and angiographic outcomes after Excel bioabsorbable polymer versus Firebird durable polymer rapamycin-eluting stent for the treatment of coronary artery disease in a "real world" setting: six-month follow-up results. Chin Med J 2007;120:574-7.
60. Costa RA, Lansky AJ, Mintz GS, Mehran R, Tsuchiya Y, Negoita M et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005;95:113-6.
61. Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168-71.
62. Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006;98:464-9.
63. Kirchner GI, Meier-Weiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95.
64. Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial. Eurointerv 2006;2:286-94.
65. Ruygrok PN, Desaga M, Van Den Branden F, Rasmussen K, Suryapranata H, Dorange C et al. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. Eurointerv 2007;3:315-20.
66. Stone G. SPIRIT III. A prospective randomized trial comparing an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. One year follow-up and subgroup analysis. Presented American College of Cardiology Annual Scientific Meeting, New Orleans March 2007.
67. Stone G. Clinical, Angiographic, and IVUS results from the pivotal U.S. randomized SPIRIT III trial of the XIENCE V Everolimus Eluting Coronary Stent System in patients with coronary artery disease. Presented American College of Cardiology Annual Scientific Meeting, New Orleans March 2007.
68. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
69. Garcia-Touchard A, Burke SE, Toner JL, Cromack K, Schwartz RS. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006;27:988-93.
70. Haraguchi G, Pruitt S, Brodeur A, Collingwood R, Carter AJ, Melder RJ et al. Increased expression of eNOS by Endeavor zotarolimus-eluting stents compared to other DES in porcine coronary artery implants. Am J Cardiol 2006;98:32-3.
71. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet FA, Verdouw PD, Serruys PW et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000;83:338-45.
72. Meredith IT, Ormiston J, Whitbourn R, Kay P, Muller D, Bonan R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. Euro Intervention. 2005;1:157-64.
73. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Popma JJ et al. ENDEAVOR I Investigators. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-inhuman study. Am J Cardiol 2007;100:56M-61M.
74. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
75. Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW et al. ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7.
76. Leon M. Two-Year Results From ENDEAVOR III Point to Safety, Efficacy. Presented at American College of Cardiology 56th Annual Scientific Session March 24-27, 2007, New Orleans, Louisiana.
77. ENDEAVOR 4: A Randomized Comparison of a Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease: 8-Month Angiographic and 9- and 12-Month Clinical Results. Presented at Transcatheter Cardiovascular Therapeutics Washington. DC October 2007.
78. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D et al. On behalf of the Endeavor Resolute Investigator. Eurointerv 2007;3:50-53.
79. Meredith I, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D et al. Clinical Outcomes at 1 Year for the Next-Generation Endeavor Resolute Stent: The RESOLUTE First-In-Human Study.Am J Cardiol 2007 [abstract] presented at TCT2007
80. Costa RA, Lansky AJ, Abizaid A, Mueller R, Tsuchiya Y, Mori K et al. Angiographic results of the first human experience with the Biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 2006;98:443-6.
81. Grube E, Abizaid A, Hauptmann KE. Safety and performance evaluation of the biosensors international biolimus A9 drug eluting stent (BioMatrix) - The stealth i study long-term safety follow-up. Am J Cardiol 2007 [abstract] presented at TCT2007
82. Chevalier B, Serruys PW, Silber S, Garcia E, Suryapranata H, Hauptmann K et al. for the Nobori 1 Clinical Investigators. Eurointerv 2007;2:426-434.
83. Grube E, Buellesfeld L, Neumann FJ, Verheye S, Abizaid A, McClean D et al. Six-month clinical and angiographic results of a dedicated drug- eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol 2007;99:1691-7.
84. Miyazawa A, Ako J, Hassan A, Hasegawa T, Abizaid A, Verheye S et al. Analysis of bifurcation lesions treated with novel drug-eluting dedicated bifurcation stent system: Intravascular ultrasound results of the AXXESS PLUS trial. Catheter Cardiovasc Interv 2007;70:952-7.
85. Evans L, Doran P, Marco P. XTENT© Custom NX drug eluting stent systems. Eurointervention 2007;3:158-61.
86. Zollinger M, Waldmeier F, Hartmann S, Zenke G, Zimmerlin AG, Glaenzel U et al. Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drag Metab Dispos 2006;34:765-74.
87. Berg R, Aragon J, Royter V, Shanley JF, Cogert G, Vermani R et al. Pimecrolimus and Dual Pimecrolimus-Paclitaxel Eluting Stents Decrease Neointimal Proliferation in a Porcine Model. Cath Cardiov Interv 2007;70:871-9.
88. Luscher TF, Tanner FC. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 2005;112:2002-11.
89. Tanimoto S, van der Giessen WJ, van Beusekom HM, Sorop O. Kukreja N, Fukaya K et al. Mahoroba™: Tacrolimus eluting coronary stent, Eurointerv 2007;3:149-53.
90. Abizaid A. The Elixir novolimus-eluting durable polymer stent: results from the EXELA First-in-Man Study. Presented at Transcatheter Cardiovascular Therapeutics Washington. DC October 2007: First -in-Man Experiences with Drug-Eluting Stents I and Passive and Active Stent Coatings.
91. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol 1999;10:499-506.
92. Tepe G, Wendel HP, Khorchidi S, Schmehl J, Wiskirchen J, Pusich B et al. Thrombogenicity of various endovascular stent types: an in vitro evaluation. J Vasc Interv Radiol 2002;13:1029-35.
93. Vogt F, Stein A, Rettemeier G, Krott N, Hoffmann R, vom Dahl J et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary poly-lactide stent. Eur Heart J 2004;25:1330-40.
94. Serruys PW. The ABSORB First-in-Man Clinical Trial: Early and late clinical outcomes and IVUS mechanistic insights. Symposium at Transcatheter Cardiovascular Therapeutics Washington. DC October 2007: Bioabsorbable stent designs: the next frontier?
95. Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR et al. PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-75.
96. M, Erbel R. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy Tsujino I, Ako J, Honda Y, Fitzgerald PJ. Drug delivery via nanomicro and macroporous coronary stent surfaces. Expert Opin Drug Deliv 2007;4:287-95.
97. Mehilli J. ISAR-TEST-3: A prospective, randomized comparison of sirolimus-eluting stents using a durable polymer,a bio-absorbable polymer, and no polymers-month clinical and angiographic results. Presented at transcatheter cardiovascular therapeutics Washington, DC October 2007.
98. Abizaid A. The MIV polymer-free hydroxyapatite-coated sirolimus-eluting stent: First-in-man angiographic and IVUS follow-up results. Presented at transcatheter cardiovascular therapeutics Washington. DC October 2007: First -in-man experiences with drug-eluting stents I and passive and active stent coatings.